Intralymphatic immunotherapy and vaccination in mice

Journal of Visualized Experiments

Volumn , Issue 84, 2014, Pages

  Johansen, Pål ^a   Kündig, Thomas M ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Adjuvants; Anesthesia; Immunization; Immunology; Intralymphatic immunotherapy; Issue 84; Lymph node injection; Surgery; Vaccination; Vaccines

Indexed keywords

VACCINE;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; CBA MOUSE; FEMALE; IMMUNOLOGY; INTRALYMPHATIC DRUG ADMINISTRATION; LYMPH NODE; MALE; METHODOLOGY; MOUSE; VACCINATION;

ANIMALS; FEMALE; INJECTIONS, INTRALYMPHATIC; LYMPH NODES; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED CBA; VACCINATION; VACCINES;

EID: 84904541725     PISSN: 1940087X     EISSN: None     Source Type: Journal    
DOI: 10.3791/51031     Document Type: Article

References (33)

1. Johansen, P. et al. Direct intralymphatic injection of peptide vaccines enhances immunogenicity. Eur. J. Immunol. 35, 568-574 (2005).
2. Maloy, K. J. et al. Intralymphatic immunization enhances DNA vaccination. Proc. Natl. Acad. Sci. U.S.A. 98, 3299-3303 (2001).
3. Smith, K. A. et al. Enhancing DNA vaccination by sequential injection of lymph nodes with plasmid vectors and peptides. Vaccine. 27, 2603-2615 (2009).
4. Kreiter, S. et al. Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity. Cancer Res. 70, 9031-9040 (2010).
5. Johansen, P. et al. Antigen kinetics determines immune reactivity. Proc. Natl. Acad. Sci. U.S.A. 105, 5189-5194 (2008).
6. Smith, K. A. et al. Lymph node-targeted immunotherapy mediates potent immunity resulting in regression of isolated or metastatic human papillomavirus-transformed tumors. Clin. Cancer Res. 15, 6167-6176 (2009).
7. Johansen, P. et al. Toll-like receptor ligands as adjuvants in allergen-specific immunotherapy. Clin. Exp. Allergy. 35, 1591-1598 (2005).
8. Johansen, P. et al. Heat denaturation, a simple method to improve the immunotherapeutic potential of allergens. Eur. J. Immunol. 35, 3591-3598 (2005).
9. Martinez-Gomez, J. M. et al. Intralymphatic injections as a new administration route for allergen-specific immunotherapy. Int. Arch. Allergy Immunol. 150, 59-65 (2009).
10. Martinez-Gomez, J. M. et al. Targeting the MHC class II pathway of antigen presentation enhances immunogenicity and safety of allergen immunotherapy. Allergy. 64, 172-178 (2009).
11. Mohanan, D. et al. Administration routes affect the quality of immune responses: A cross-sectional evaluation of particulate antigen-delivery systems. J. Control Release. 147, 342-349 (2010).
12. Waeckerle-Men, Y. et al. Lymph node targeting of BCG vaccines amplifies CD4 and CD8 T-cell responses and protection against Mycobacterium tuberculosis. Vaccine. 31, 1057-1064 (2013).
13. von Beust, B. R. et al. Improving the therapeutic index of CpG oligodeoxynucleotides by intralymphatic administration. Eur. J. Immunol. 35, 1869-1876 (2005).
14. Senti, G. et al. Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections. J. Allergy Clin. Immunol. 129, 1290-1296 (2012).
15. Senti, G. et al. Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial. Proc. Natl. Acad. Sci. U.S.A. 105, 17908-17912 (2008).
16. Lesterhuis, W. J. et al. Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients. Clin. Cancer Res. 17, 5725-5735 (2011).
17. Fadul, C. E. et al. Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy. J. Immunother. 34, 382-389 (2011).
18. Eizenberg, P. et al. Acceptance of Intanza(R) 9 mug intradermal influenza vaccine in routine clinical practice in Australia and Argentina. Adv. Ther. 28, 640-649 (2011).
19. Durando, P. et al. Adjuvants and alternative routes of administration towards the development of the ideal influenza vaccine. Hum. Vaccin. 7 Suppl, 29-40 (2011).
20. Barth, R. J., Jr. et al. A randomized trial of ex vivo CD40L activation of a dendritic cell vaccine in colorectal cancer patients: tumor-specific immune responses are associated with improved survival. Clin. Cancer Res. 16, 5548-5556 (2010).
21. Schwaab, T. et al. Clinical and immunologic effects of intranodal autologous tumor lysate-dendritic cell vaccine with Aldesleukin (Interleukin 2) and IFN-{alpha}2a therapy in metastatic renal cell carcinoma patients. Clin. Cancer Res. 15, 4986-4992 (2009).
22. Senti, G., Johansen, P. & Kundig, T. M. Intralymphatic immunotherapy. Curr. Opin. Allergy Clin. Immunol. 9, 537-543 (2009).
23. Catron, D. M., Itano, A. A., Pape, K. A., Mueller, D. L. & Jenkins, M. K. Visualizing the first 50 hr of the primary immune response to a soluble antigen. Immunity. 21, 341-347 (2004).
24. Itano, A. A. & Jenkins, M. K. Antigen presentation to naive CD4 T cells in the lymph node. Nat. Immunol. 4, 733-739 (2003).
25. Johansen, P., Mohanan, D., Martinez-Gomez, J. M., Kundig, T. M. & Gander, B. Lympho-geographical concepts in vaccine delivery. J. Control Release.148, 56-62 (2010).
26. Johansen, P., von Moos, S., Mohanan, D., Kundig, T. M. & Senti, G. New routes for allergen immunotherapy. Hum. Vacc. Immunother. 8, 1525-1533 (2012).
27. Senti, G., Johansen, P. & Kundig, T. M. Intralymphatic immunotherapy: from the rationale to human applications. Curr. Top. Microbiol. Immunol. 352, 71-84 (2011).
28. Duthie, M. S., Windish, H. P., Fox, C. B. & Reed, S. G. Use of defined TLR ligands as adjuvants within human vaccines. Immunol. Rev. 239, 178-196 (2011).
29. Ribas, A. et al. Intra-lymph node prime-boost vaccination against Melan A and tyrosinase for the treatment of metastatic melanoma: results of a phase 1 clinical trial. Clin. Cancer Res. 17, 2987-2996 (2011).
30. Bedrosian, I. et al. Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8+ T-cell function in melanoma patients. J. Clin. Oncol. 21, 3826-3835 (2003).
31. Lesimple, T. et al. Injection by various routes of melanoma antigen-associated macrophages: biodistribution and clinical effects. Cancer Immunol. Immunother. 52, 438-444 (2003).
32. Brown, K. et al. Adenovirus-transduced dendritic cells injected into skin or lymph node prime potent simian immunodeficiency virus-specific T cell immunity in monkeys. J. Immunol. 171, 6875-6882 (2003).
33. Fong, L., Brockstedt, D., Benike, C., Wu, L. & Engleman, E. G. Dendritic cells injected via different routes induce immunity in cancer patients. J. Immunol.166, 4254-4259 (2001).